Project Grant R43DA050384

The U.S. National Institute on Drug Abuse (NIDA) awarded Altrumed LLC a $404,078 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a device-agnostic hypoxia detection software for opioid overdose prediction and positive reversal monitoring. The project, titled "DEVICE-AGNOSTIC HYPOXIA DETECTION SOFTWARE FOR OVERDOSE PREDICTION AND POSITIVE REVERSAL MONITORING," aims to create an innovative wearable sensor system that integrates advanced...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $889,713 to The Ohio State University from April 2021 through March 2023. The funding supports research to develop dual-cavity baskets assembled into nanoparticles as nano-antidotes for overdose with fentanyl and its derivatives. Specifically, the awardee will functionalize dual-cavity baskets with biocompatible groups to trap...

The National Institute on Drug Abuse (NIDA), through its Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $2,612,736 Cooperative Agreement to Cessation Therapeutics, Inc. to advance the clinical development of their anti-fentanyl monoclonal antibody, CSX-1004. The goal is to conduct a Phase 2, proof-of-concept fentanyl challenge study in healthy subjects and those with opioid use disorder. The ultimate target product profile is a fixed-dose, subcutaneous injection that can be...

This federal Project Grant award of $399,997 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of neural exosome therapeutics for treating opioid-induced brain hypoxia injuries. The grantee, Aruna Bio Inc., is leveraging its patented neural exosome platform technology, AB126, to demonstrate the anti-inflammatory and neuroprotective effects of these exosomes in preclinical models of opioid-induced brain...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...

This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,664,000.00 in funding to The Washington University to develop negative allosteric modulators (NAMs) of the mu opioid receptor as potential treatments for opioid overdose and opioid use disorder. The key products and services to be delivered through this 2-year award, which runs from September 1, 2025 to August 31, 2027, include...

This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,932,500.00 in funding to The Drug Delivery Company, LLC to develop a bioabsorbable, subcutaneous, extended-release buprenorphine implant for the treatment of opioid use disorder. The project aims to build upon the company's successful development of a 6-month bioabsorbable naltrexone implant, known as ISTEP-N, which demonstrated the...

This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...

This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $640,000 to Olfa Thera, Inc. to develop new therapeutics targeting the OLFR78/OR51E2 receptor pathway in the carotid body. The goal is to identify OLFR78/OR51E2 agonists that can strongly stimulate carotid body activity and ventilation to reverse opioid-induced respiratory depression, without the side effects of existing...

This $2,668,301 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant funds the development of an implantable, biodegradable drug delivery device for localized, long-duration administration of non-opioid pain medications after surgery. The University of Connecticut will synthesize protein-based film materials conjugated with...